RoboNurse by Toronto Rehabilitation Institute

Tuesday, February 21, 2012 - 6:30pm

Individuals in the healthcare industry suffer from a high rate of workplace related injuries when compared to other industries; this is especially true for nurses. In particular, nurses are at a high risk for low-back injuries, as lifting-related activities associated with patient transferring, are closely related to such injuries. Numerous studies suggest that the use of patient handling and transferring technologies in the healthcare setting reduce the incidence of injuries. However, evaluations of existing technologies demonstrate several limitations – space restriction, high investment costs, and poor patient cooperation.

The Toronto Rehabilitation Institute is Canada’s largest academic adult rehabilitation hospital and is known as a leader in rehabilitation science. The iDAPT (Intelligence Design for Adaptation, Participation and Technology) team at Toronto Rehab has designed an innovative, ride-on lifting device called RoboNurse. RoboNurse has the ability to assist caregivers and nurses in lifting and transferring patients under controlled robotic power. This device is expected to reduce low-back loading and the burden that caregivers experience when handling individuals, especially bariatric patients. While still in the developmental stage, Toronto Rehab has partnered with leading Canadian and Chinese manufacturers to bring this revolutionary device to market. Currently, studies evaluating the clinical benefit of RoboNurse have yet to be implemented. Now, Team 4S.I.Te proposes a study that will assess the efficacy of RoboNurse in the Canadian hospital setting. The primary endpoint will be the measure of low-back injuries; however, this study will examine multiple validated measures in order to decisively determine if RoboNurse is safe and effective.   

Team 4S.I.Te

Team 4S.I.Te: Amani Akhtar, Ian Engson, Stephanie Gonzalez, Geoff Reid

Tuesday, February 21, 2012, 6:30-7:30pm, Instructional Centre, Room 335. Also available via webcast. Open to the public.

The Master of Biotechnology Program would like to thank AstraZeneca Canada Inc. for their continued support of this seminar series.